Inhibition of the Immunoproteasome Ameliorates Experimental Autoimmune Encephalomyelitis

Overview

Journal EMBO Mol Med

Specialty Molecular Biology

Date 2014 Jan 9

PMID 24399752

Citations 85

Authors

Michael Basler

Sarah Mundt

Tony Muchamuel

Carlo Moll

Jing Jiang

Marcus Groettrup

Christopher J Kirk

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system. The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes. Recently, we demonstrated a novel function of immunoproteasomes in cytokine production and T cell differentiation. In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS. ONX 0914 attenuated disease progression after active and passive induction of experimental autoimmune encephalomyelitis (EAE), both in MOG₃₅-₅₅ and PLP₁₃₉₋₁₅₁-induced EAE. Isolation of lymphocytes from the brain or spinal cord revealed a strong reduction of cytokine-producing CD4(+) cells in ONX 0914 treated mice. Additionally, ONX 0914 treatment prevented disease exacerbation in a relapsing-remitting model. An analysis of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice. These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.

Citing Articles

Inhibition of Immunoproteasome Attenuates NLRP3 Inflammasome Response by Regulating E3 Ubiquitin Ligase TRIM31.

Lee Y, Yoon B, Son S, Cho E, Kim K, Choi E Cells. 2024; 13(8.

PMID: 38667290 PMC: 11048918. DOI: 10.3390/cells13080675.

Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice.

Schaftenaar F, van Dam A, de Bruin G, Depuydt M, de Mol J, Amersfoort J Arterioscler Thromb Vasc Biol. 2024; 44(6):1346-1364.

PMID: 38660806 PMC: 11188635. DOI: 10.1161/ATVBAHA.123.319701.

Pharmacological induction of autophagy reduces inflammation in macrophages by degrading immunoproteasome subunits.

Zhou J, Li C, Lu M, Jiang G, Chen S, Li H PLoS Biol. 2024; 22(3):e3002537.

PMID: 38447109 PMC: 10917451. DOI: 10.1371/journal.pbio.3002537.

Interplay between proteasome function and inflammatory responses in e-cig vapor condensate-challenged lung epithelial cells.

Begum R, Thota S, Batra S Arch Toxicol. 2023; 97(8):2193-2208.

PMID: 37344694 DOI: 10.1007/s00204-023-03504-5.

Chronic Administration of Non-Constitutive Proteasome Inhibitor Modulates Long-Term Potentiation and Glutamate Signaling-Related Gene Expression in Murine Hippocampus.

Maltsev A, Funikov S, Rezvykh A, Teterina E, Nebogatikov V, Burov A Int J Mol Sci. 2023; 24(9).

PMID: 37175876 PMC: 10179285. DOI: 10.3390/ijms24098172.

References

Bennett M, Kirk C . Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel. 2008; 11(5):616-25. View

Rockwell C, Monaco J, Qureshi N . A critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes. Pharmacology. 2012; 89(3-4):117-26. PMC: 3702019. DOI: 10.1159/000336335. View

Lassmann H . Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol. 2005; 15(3):217-22. PMC: 8095927. DOI: 10.1111/j.1750-3639.2005.tb00523.x. View

Adams J, Palombella V, Sausville E, Johnson J, Destree A, Lazarus D . Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59(11):2615-22. View

Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C . Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol. 2008; 38(9):2401-11. DOI: 10.1002/eji.200838413. View

Van Kaer L, Ashton-Rickardt P, Eichelberger M, Gaczynska M, Nagashima K, Rock K . Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity. 1994; 1(7):533-41. DOI: 10.1016/1074-7613(94)90043-4. View

Basler M, Moebius J, Elenich L, Groettrup M, Monaco J . An altered T cell repertoire in MECL-1-deficient mice. J Immunol. 2006; 176(11):6665-72. DOI: 10.4049/jimmunol.176.11.6665. View

Muchamuel T, Basler M, Aujay M, Suzuki E, Kalim K, Lauer C . A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009; 15(7):781-7. DOI: 10.1038/nm.1978. View

Groll M, Berkers C, Ploegh H, Ovaa H . Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006; 14(3):451-6. DOI: 10.1016/j.str.2005.11.019. View

10.

Frausto R, Crocker S, Eam B, Whitmire J, Whitton J . Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency. J Neuroimmunol. 2007; 192(1-2):124-33. PMC: 2175388. DOI: 10.1016/j.jneuroim.2007.09.024. View

11.

Kuhn D, Hunsucker S, Chen Q, Voorhees P, Orlowski M, Orlowski R . Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2008; 113(19):4667-76. PMC: 2680370. DOI: 10.1182/blood-2008-07-171637. View

12.

Moebius J, van den Broek M, Groettrup M, Basler M . Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol. 2010; 40(12):3439-49. DOI: 10.1002/eji.201040620. View

13.

Schwarz K, van den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G . Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol. 2000; 165(2):768-78. DOI: 10.4049/jimmunol.165.2.768. View

14.

Peters J, Franke W, Kleinschmidt J . Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem. 1994; 269(10):7709-18. View

15.

Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski U . The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem. 1995; 270(40):23808-15. DOI: 10.1074/jbc.270.40.23808. View

16.

Sijts A, Standera S, Toes R, Ruppert T, Beekman N, van Veelen P . MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J Immunol. 2000; 164(9):4500-6. DOI: 10.4049/jimmunol.164.9.4500. View

17.

Whitehouse D, Whitehouse M, Pearson C . Passive transfer of adjuvant-induced arthritis and allergic encephalomyelitis in rats using thoracic duct lymphocytes. Nature. 1969; 224(5226):1322. DOI: 10.1038/2241322a0. View

18.

Poppensieker K, Otte D, Schurmann B, Limmer A, Dresing P, Drews E . CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc Natl Acad Sci U S A. 2012; 109(10):3897-902. PMC: 3309768. DOI: 10.1073/pnas.1114153109. View

19.

Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H . Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002; 8(5):500-8. DOI: 10.1038/nm0502-500. View

20.

Singh A, Bandi M, Aujay M, Kirk C, Hark D, Raje N . PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2010; 152(2):155-63. PMC: 3138210. DOI: 10.1111/j.1365-2141.2010.08491.x. View